The 36-month beta value for ORIC is also noteworthy at 1.20. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ORIC is 42.30M, and at present, short sellers hold a 24.70% of that float. The average trading volume of ORIC on February 20, 2025 was 799.83K shares.
ORIC) stock’s latest price update
The stock price of ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has jumped by 1.15 compared to previous close of 7.85. Despite this, the company has seen a fall of -19.39% in its stock price over the last five trading days. globenewswire.com reported 2025-02-18 that Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC
ORIC’s Market Performance
ORIC’s stock has fallen by -19.39% in the past week, with a monthly drop of -17.12% and a quarterly drop of -10.08%. The volatility ratio for the week is 17.06% while the volatility levels for the last 30 days are 14.28% for ORIC Pharmaceuticals Inc The simple moving average for the last 20 days is -23.07% for ORIC’s stock, with a simple moving average of -15.31% for the last 200 days.
Analysts’ Opinion of ORIC
Many brokerage firms have already submitted their reports for ORIC stocks, with Wells Fargo repeating the rating for ORIC by listing it as a “Overweight.” The predicted price for ORIC in the upcoming period, according to Wells Fargo is $20 based on the research report published on October 31, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see ORIC reach a price target of $20. The rating they have provided for ORIC stocks is “Buy” according to the report published on September 06th, 2024.
ORIC Trading at -15.45% from the 50-Day Moving Average
After a stumble in the market that brought ORIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.31% of loss for the given period.
Volatility was left at 14.28%, however, over the last 30 days, the volatility rate increased by 17.06%, as shares sank -20.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.98% lower at present.
During the last 5 trading sessions, ORIC fell by -19.39%, which changed the moving average for the period of 200-days by -14.90% in comparison to the 20-day moving average, which settled at $10.32. In addition, ORIC Pharmaceuticals Inc saw -1.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ORIC starting from Piscitelli Dominic, who sale 8,851 shares at the price of $8.28 back on Dec 16 ’24. After this action, Piscitelli Dominic now owns 106,764 shares of ORIC Pharmaceuticals Inc, valued at $73,298 using the latest closing price.
Multani Pratik S, the Chief Medical Officer of ORIC Pharmaceuticals Inc, sale 8,850 shares at $8.28 during a trade that took place back on Dec 16 ’24, which means that Multani Pratik S is holding 46,765 shares at $73,293 based on the most recent closing price.
Stock Fundamentals for ORIC
Current profitability levels for the company are sitting at:
- -87.62 for the present operating margin
- 0.48 for the gross margin
The net margin for ORIC Pharmaceuticals Inc stands at -77.94. The total capital return value is set at -0.48. Equity return is now at value -54.73, with -48.12 for asset returns.
Based on ORIC Pharmaceuticals Inc (ORIC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -35.01. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -67.85.
Currently, EBITDA for the company is -142.9 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 337.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.56.
Conclusion
In summary, ORIC Pharmaceuticals Inc (ORIC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
